[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370656-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370656-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","puma-reduces-fasn-ubiquitination-to-promote-lipid-accumulation-and-tumor-progression-in-human-clear-cell-renal-cell-carcinoma","PUMA reduces FASN ubiquitination to promote lipid accumulation and tumor progression in human clear cell renal cell carcinoma","","PUMA (p53 upregulated modulator of apoptosis) is shown to have an oncogenic function in clear cell renal cell carcinoma (ccRCC) that differs from its established pro-apoptotic role. High PUMA expression correlates with advanced clinical stages and poor prognosis, and its impact on ccRCC progression appears apoptosis-independent. Mechanistically, PUMA interacts with FASN via an N44-102 sequence, stabilizing FASN by binding USP15 and lowering FASN ubiquitination and degradation. PUMA knockdown suppresses tumor growth and increases sensitivity to metabolic inhibition, and combined PUMA and FASN inhibition highlights a therapeutic metabolic axis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/puma-reduces-fasn-ubiquitination-to-promote-lipid-accumulation-and-tumor-progression-in-human-clear-cell-renal-cell-carcinoma/370656/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/puma-reduces-fasn-ubiquitination-to-promote-lipid-accumulation-and-tumor-progression-in-human-clear-cell-renal-cell-carcinoma/370656.png","ImageObject",300,407,{"name":42,"@type":43},"Melati","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What new role does PUMA play in clear cell renal cell carcinoma?","Question",{"text":63,"@type":64},"PUMA promotes tumor progression and lipid accumulation in ccRCC through a mechanism distinct from its traditional pro-apoptotic function.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does PUMA affect fatty acid synthase (FASN)?",{"text":68,"@type":64},"PUMA stabilizes FASN by binding USP15, which reduces FASN ubiquitination and degradation.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the significance of the PUMA N44-102 sequence?",{"text":72,"@type":64},"The N44-102 amino acid sequence of PUMA is crucial for its interaction with FASN, distinct from the previously studied BH3 domain.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370656,1790621064,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nPUMA reduces FASN ubiquitination to promote lipid accumulation and tumor progression in human clear cell renal cell carcinoma  \nQianqian Luo1, Qi Wang2, Jian Shi2, Qingyang LV2, Zirui Dong2, Wen Li1, Yaru Xia 1, Jingchong Liu2 and Hongmei Yang 1 ✉  \n© The Author(s) 2025  \n|  |  |  |\n| --- | --- | --- |\n|  | While the p53 upregulated modulator of apoptosis (PUMA) is traditionally recognized for promoting cell apoptosis and enhancing chemotherapy efﬁcacy in various cancers, its role in clear cell renal cell carcinoma (ccRCC) remains unclear due to ccRCC’s chemotherapy resistance. In this study, we discover a novel oncogenic role for PUMA in ccRCC, diverging from its known apoptotic function, through assessments of public datasets, clinical tissue samples, and cell line experiments. Abnormally high expression of PUMA positively correlates with clinical stages and poor prognosis. Notably, PUMA’s role in ccRCC appears to be independent of apoptosis. Instead, it facilitates tumor progression and lipid accumulation through mechanisms involving the key metabolic regulator, fatty acid synthase (FASN) . Speciﬁcally, the N44-102 amino acid sequence of PUMA, distinct from the previously studied BH3 domain, is crucial for its interaction with FASN. As a mechanism, PUMA stabilizes FASN by binding to ubiquitin-speciﬁc protease 15 (USP15), reducing FASN ubiquitination and degradation, thereby forming the PUMA-USP15-FASN axis. These ﬁndings challenge the established view of PUMA’s role in cancer biology. Furthermore, PUMA knockdown signiﬁcantly inhibits tumor growth and enhances the sensitivity of ccRCC tumors to metabolic inhibition. These results position PUMA as a novel metabolic regulator and a potential therapeutic target in ccRCC. The combined inhibition of PUMA and FASN further supports the therapeutic |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| potential of targeting this metabolic axis. |  |  |\n|  | Cell Death and Disease (2025)16:460; [https://doi.org/10.1038/s41419-025-07782-y](https://doi.org/10.1038/s41419-025-07782-y) |  |\n|  |  |  |\n\nINTRODUCTION  \nRenowned for its aggressive invasion and high metastasis rates, clear cell renal cell carcinoma (ccRCC) is responsible for over 90% of deaths resulting from kidney cancers [1, 2] . While ccRCCis characterized by multiple gene mutations, mutations in the VHL gene commonly lead to the accumulation of hypoxiainducible factor (HIF) . This leads to a series of aberrations in pathways, such as vascular endothelial growth factor (VEGF) and mTOR [3, 4] . Researchers and drug producers have targeted these mutated genes and abnormal molecules to develop therapies for ccRCC. The recent approval of the HIF-2α inhibitor Belzutifan represents a notable outcome of this research direction [5] . However, patients with ccRCC often acquire resistance to current ﬁrst-line drugs, such as VEGF inhibitors, tyrosine kinase inhibitors, and mTOR inhibitors, which ultimately reduces survival [6] . These challenges highlight the need for earlier diagnosis and the identiﬁcation of novel mechanismsand therapeutic targets for ccRCC.  \nNotably, abnormal lipid metabolism has emerged as a critical aspect of ccRCC. Lipid droplets within ccRCC cells are a key pathological feature and play a crucial role in stabilizing the endoplasmic reticulum and promoting tumor cell survival [7] . Key enzymes involved in lipid biosynthesis, such as fatty acid  \nsynthase (FASN), are upregulated in ccRCC and are linked with poor prognosis [8] . Furthermore, recent studies, including our own, have highlighted a signiﬁcant link between lipid accumulation and the oncogenic factor HIF-2α, suggesting that targeting lipid metabolism pathways, including key enzymes like FASN, could provide new therapeutic opportunities forccRCC [9–11] .  \nThe tumor suppressor gene p53 is well known for it","cbCaimC90upnYuQV","https://ap.wps.com/l/cbCaimC90upnYuQV","pdf",10516065,18,"English","# Introduction\n## Clear cell renal cell carcinoma and therapeutic resistance\n## Lipid metabolism and FASN in ccRCC\n## p53 pathway, PUMA, and rationale for investigating PUMA in ccRCC","[{\"question\":\"What new role does PUMA play in clear cell renal cell carcinoma?\",\"answer\":\"PUMA promotes tumor progression and lipid accumulation in ccRCC through a mechanism distinct from its traditional pro-apoptotic function.\"},{\"question\":\"How does PUMA affect fatty acid synthase (FASN)?\",\"answer\":\"PUMA stabilizes FASN by binding USP15, which reduces FASN ubiquitination and degradation.\"},{\"question\":\"What is the significance of the PUMA N44-102 sequence?\",\"answer\":\"The N44-102 amino acid sequence of PUMA is crucial for its interaction with FASN, distinct from the previously studied BH3 domain.\"}]","PUMA reduces FASN ubiquitination to promote lipid accumulation and tumor progression in human clear cell renal cell carcinoma | PDF",1790189670,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfd5da97a6ca7f63031709cb8be91168.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b38ae7597fe9c66d3138da71f455c95e.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97f50c1e4a33e65df8dcef137f4cc2bf.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bab6e532447c30f3ffcc2bbc8b267e8e.webp",980,1301]